RTP Mobile Logo
Prostate Cancer Update Think Tank Companion CME Activity – Video Module II: Controversies in the Management of PSA-Only Recurrent Disease
Released February 2011

Dr Stephen J Freedland discusses controversies on the timing and selection of therapy in the management of PSA-only recurrent disease and the ongoing clinical trials for this patient population.

CE Disclosures and Faculty Information


    This activity is intended for medical oncologists, urologists and radiation oncologists.

    • Apply the results of current research to the best-practice surgical, radiation and/or systemic treatment of localized and PSA-only recurrent disease.
    • Identify patients with biochemical relapse who may benefit from immediate versus delayed therapeutic interventions.
    • Counsel appropriately selected patients about the availability of ongoing clinical trial participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity contains a video component and downloadable slides. The participant should watch the video content.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Stephen J Freedland, MD
    Attending Physician, Durham VA Medical Center
    Associate Professor of Urology and Pathology
    Duke Prostate Center, Duke University School of Medicine
    Durham, North Carolina

    Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Myriad Genetics Inc; Consulting Agreement: Amgen Inc; Speakers Bureau: Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc.

    EDITOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium Pharmaceuticals Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Dendreon Corporation, Millennium Pharmaceuticals Inc and Sanofi-Aventis.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: February 2011
    Expiration date: February 2012

Acknowledge and close

Watch video
(WIFI is recommended for best performance):